Sugi Predict

Sugi Predict / Compounds / SCHEMBL217907

SCHEMBL217907

SCHEMBL217907

Clc1ccc(Oc2[c]cccn2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.40
▸ L3MBTL1 Q9Y468 4/20 0.39
▸ NPC1 O15118 3/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ SCN9A Q15858 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ MAOA P21397 1/20 0.38
▸ MAOB P27338 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ MEN1 O00255 3/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ LTA4H P09960 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ POLB P06746 1/20 0.36
▸ CASP3 P42574 1/20 0.35
▸ SENP8 Q96LD8 1/20 0.35
▸ SENP7 Q9BQF6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL316115 0.83 LTA4H (0.42) RAB9ANPC1HTTMAOAKDM4E
SCHEMBL8128538 0.82 MAPT (0.38) RAB9ANPC1SMN1; SMN2HTTKDM4E
SCHEMBL8129794 0.82 CLK4 (0.47) RAB9ANPSR1L3MBTL1NPC1SMN1; SMN2
SCHEMBL1031471 0.82 KMT2A (0.44) RAB9ANPSR1L3MBTL1NPC1SMN1; SMN2
SCHEMBL314481 0.82 KMT2A (0.39) RAB9AL3MBTL1SCN9AHTTKDM4E
SCHEMBL9900619 0.82 MEN1 (0.56) RAB9AL3MBTL1NPC1SMN1; SMN2MAOA
SCHEMBL8122786 0.74 LMNA (0.50) SMN1; SMN2HTTALDH1A1LTA4H
SCHEMBL7672173 0.74 ALDH1A1 (0.41) RAB9ANPC1SCN9AHTTMAPK1
SCHEMBL27267264 0.72 MEN1 (0.63) RAB9ANPSR1L3MBTL1NPC1SMN1; SMN2
SCHEMBL4342200 0.71 MAP4K4 (0.38) KDM4EALDH1A1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110092788-B Substituted [1,2,4] triazolo [1,5-a ] pyrimidin-7-yl compounds as PDE2 inhibitors 达特神经科学(开曼)有限公司 2022-02-25 — — CN claimed
EP-3597649-B1 COMPOSITIONS CONTAINING SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS DART NEUROSCIENCE CAYMAN LTD (KY) 2021-10-13 — — EP claimed
EP-3134413-B1 SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS DART NEUROSCIENCE CAYMAN LTD (KY) 2019-09-11 — — EP claimed
CN-110092788-A Substituted [1,2,4] triazol [1,5-a] pyrimidin-7-yl compound as PDE2 inhibitor 达特神经科学(开曼)有限公司 2019-08-06 — — CN claimed
US-9932345-B2 Substituted [1,2,4]triazolo[1,5-A]pyrimidin-7-yl compounds as PDE2 inhibitors DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2018-04-03 — — US claimed
US-20170057967-A1 SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS DART NEUROSCIENCE LLC 2017-03-02 — — US claimed
EP-3134413-A1 SUBSTITUTED [1,2,4]TRIAZOLO [1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS Dart Neuroscience (Cayman) Ltd (KY) 2017-03-01 — — EP claimed
CN-106459062-A Substituted [1,2,4] triazolo [1,5-a ] pyrimidin-7-yl compounds as PDE2 inhibitors 达特神经科学(开曼)有限公司 2017-02-22 — — CN claimed
WO-2015164508-A1 SUBSTITUTED [1,2,4] TRIAZOLO [1,5-A] PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS DART NEUROSCIENCE, LLC (US) 2015-10-29 — — WO claimed
CN-101384544-B Substituted cyclohexylmethyl derivatives GRUENENTHAL GMBH 2014-01-22 — — CN claimed
EP-1989174-A1 SUBSTITUTED CYCLOHEXYLMETHYL DERIVATIVES Grünenthal GmbH (DE) 2008-11-12 — — EP claimed
US-20070287726-A1 5-Substituted 1H-Pyrrolo [3,2-B] Pyridines ALTANA PHARMA AG (DE) 2007-12-13 — — US claimed
WO-2007079930-A1 SUBSTITUTED CYCLOHEXYLMETHYL DERIVATIVES Grünenthal GmbH (DE) 2007-07-19 — — WO claimed
EP-1776361-A1 5-SUBSTITUTED 1H-PYRROLOÝ3,2-B¨PYRIDINES Altana Pharma AG (DE) 2007-04-25 — — EP claimed
CN-1791412-A Novel compounds and their use in therapy SOLVAY PHARM GMBH (NL) 2006-06-21 — — CN claimed
EP-1635839-A2 BENZO[4,5]THIENO[2,3-D]PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY Solvay Pharmaceuticals B.V. (NL) 2006-03-22 — — EP claimed
WO-2006013195-A1 5-SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINES ALTANA PHARMA AG (DE) 2006-02-09 — — WO claimed
US-20050176742-A1 Novel compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2005-08-11 — — US claimed
WO-2005032527-A2 BENZO (4, 5) THIENO (2, 3-D) PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY SOLVAY PHARMACEUTICALS B.V. (NL) 2005-04-14 — — WO claimed
US-20050038053-A1 Novel compounds and their use in therapy SOLVAY PHARMACEUTICALS B.V. (NL) 2005-02-17 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287726-A1 5-Substituted 1H-Pyrrolo [3,2-B] Pyridines GIPR, VIP, PGC RAB9A 986/4885NPSR1 271/4885L3MBTL1 4524/4885
US-20050176742-A1 Novel compounds and their use in therapy HSD17B11, HSD17B2, HSD17B1 RAB9A 3568/4885NPSR1 1796/4885L3MBTL1 3522/4885
US-20170057967-A1 SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS PDE12, PDE2A, TDP2 RAB9A 1017/4885NPSR1 1305/4885L3MBTL1 3359/4885
US-20050038053-A1 Novel compounds and their use in therapy HSD17B11, HSD17B2, HSD17B1 RAB9A 3568/4885NPSR1 1796/4885L3MBTL1 3522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.